116 related articles for article (PubMed ID: 8675231)
61. Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression.
Robertson MJ; Schacterle RS; Mackin GA; Wilson SN; Bloomingdale KL; Ritz J; Komaroff AL
Clin Exp Immunol; 2005 Aug; 141(2):326-32. PubMed ID: 15996197
[TBL] [Abstract][Full Text] [Related]
62. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
[TBL] [Abstract][Full Text] [Related]
63. [Therapy of chronic fatigue syndrome].
Uchida A
Nihon Rinsho; 1992 Nov; 50(11):2679-83. PubMed ID: 1287242
[TBL] [Abstract][Full Text] [Related]
64. Increased Natural Killer Cell Activation in HIV-Infected Immunologic Non-Responders Correlates with CD4+ T Cell Recovery after Antiretroviral Therapy and Viral Suppression.
Luo Z; Li Z; Martin L; Hu Z; Wu H; Wan Z; Kilby M; Heath SL; Huang L; Jiang W
PLoS One; 2017; 12(1):e0167640. PubMed ID: 28076376
[TBL] [Abstract][Full Text] [Related]
65. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
[TBL] [Abstract][Full Text] [Related]
66. NK cells prevalence, subsets and function in viral hepatitis C.
Zeromski J; Mozer-Lisewska I; Kaczmarek M; Kowala-Piaskowska A; Sikora J
Arch Immunol Ther Exp (Warsz); 2011 Dec; 59(6):449-55. PubMed ID: 21972016
[TBL] [Abstract][Full Text] [Related]
67. Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B.
Gogas H; Paterakis G; Frangia K; Bafaloukos D; Pectasides D; Kalofonos HP; Loukopoulos D; Stavropoulou-Giokas C; Ioannovich J; Mihm MC
Am J Clin Oncol; 2002 Dec; 25(6):591-6. PubMed ID: 12478006
[TBL] [Abstract][Full Text] [Related]
68. Use of cryopreserved lymphocytes for assessment of the immunological effects of interferon therapy in renal cell carcinoma patients.
Sobota V; Bubeník J; Indrová M; Vlk V; Jakoubková J
J Immunol Methods; 1997 Apr; 203(1):1-10. PubMed ID: 9134025
[TBL] [Abstract][Full Text] [Related]
69. Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites.
Page ST; Plymate SR; Bremner WJ; Matsumoto AM; Hess DL; Lin DW; Amory JK; Nelson PS; Wu JD
Am J Physiol Endocrinol Metab; 2006 May; 290(5):E856-63. PubMed ID: 16352669
[TBL] [Abstract][Full Text] [Related]
70. Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial.
Roerink ME; Knoop H; Bredie SJ; Heijnen M; Joosten LA; Netea MG; Dinarello CA; van der Meer JW
Trials; 2015 Oct; 16():439. PubMed ID: 26438161
[TBL] [Abstract][Full Text] [Related]
71. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
[TBL] [Abstract][Full Text] [Related]
72. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.
Serti E; Chepa-Lotrea X; Kim YJ; Keane M; Fryzek N; Liang TJ; Ghany M; Rehermann B
Gastroenterology; 2015 Jul; 149(1):190-200.e2. PubMed ID: 25754160
[TBL] [Abstract][Full Text] [Related]
73. Dysfunction of natural killer activity in a family with chronic fatigue syndrome.
Levine PH; Whiteside TL; Friberg D; Bryant J; Colclough G; Herberman RB
Clin Immunol Immunopathol; 1998 Jul; 88(1):96-104. PubMed ID: 9683556
[TBL] [Abstract][Full Text] [Related]
74. [Alteration of CD100 expression on natural killer cells in chronic patients with hepatitis C virus before and after initiation of antiviral treatment].
He Y; Li B; Zhou Y; Zhang Y; Guo Y; Ji G; Fan C; Jia Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Aug; 30(8):856-60. PubMed ID: 25108441
[TBL] [Abstract][Full Text] [Related]
75. Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C.
Kronenberger B; Herrmann E; Hofmann WP; Wedemeyer H; Sester M; Mihm U; Ghaliai T; Zeuzem S; Sarrazin C
J Leukoc Biol; 2006 Aug; 80(2):298-308. PubMed ID: 16735696
[TBL] [Abstract][Full Text] [Related]
76. Defective natural immunity: an early manifestation of human immunodeficiency virus infection.
Ullum H; Gøtzsche PC; Victor J; Dickmeiss E; Skinhøj P; Pedersen BK
J Exp Med; 1995 Sep; 182(3):789-99. PubMed ID: 7650485
[TBL] [Abstract][Full Text] [Related]
77. Antioxidant bioavailability and rapid immune-modulating effects after consumption of a single acute dose of a high-metabolite yeast immunogen: results of a placebo-controlled double-blinded crossover pilot study.
Jensen GS; Redman KA; Benson KF; Carter SG; Mitzner MA; Reeves S; Robinson L
J Med Food; 2011 Sep; 14(9):1002-10. PubMed ID: 21501093
[TBL] [Abstract][Full Text] [Related]
78. [Evaluation of the efficacy of wiferon and arbidol in adult influenza].
Kolobukhina LV; Malinovskaia VV; Gatich RZ; Merkulova LN; Burtseva EI; Isaeva EI; Parshina OV; Guseva TS; Orlova TG; Voronina FV
Vopr Virusol; 2008; 53(1):31-3. PubMed ID: 18318133
[TBL] [Abstract][Full Text] [Related]
79. The in vitro immunomodulatory effects of glyconutrients on peripheral blood mononuclear cells of patients with chronic fatigue syndrome.
See DM; Cimoch P; Chou S; Chang J; Tilles J
Integr Physiol Behav Sci; 1998; 33(3):280-7. PubMed ID: 9829439
[TBL] [Abstract][Full Text] [Related]
80. Effects of cyclosporin A upon humoral and cellular immune parameters in insulin-dependent diabetes mellitus type I: a long-term follow-up study.
Müller C; Zielinski CC; Kalinowski W; Wolf H; Mannhalter JW; Aschauer-Treiber G; Klösch-Kasparek D; Gaube S; Eibl MM; Schernthaner G
J Endocrinol; 1989 Apr; 121(1):177-83. PubMed ID: 2654321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
